CD Patients Immune Status Evaluation

N/ACompletedNCT04135482

First Affiliated Hospital of Zhejiang University10 enrolled

Overview

Using single cell sequencing method to evaluate and compare the immune status of patients with severe CD.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Severe Crohn's Diease

Interventions

colonic tissue biopsyOTHER

colonic tissue biospy of patients with severe crohn's disease using colonoscopy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1, Patients with severe CD（CDAI\>16,SES-CD\>19） 2, Patients have no previous any drug therapy targeting CD or just received treatment of 5-ASA - Exclusion Criteria: 1, patients have previous treatment of prednisone, immunosuppressive agents such as azathioprine and biologic agents such as infliximab 2, patients were diagnozed as mild-moderate CD 3, patients have other immune disordered diseases such as SLE, PBC, AIH, PSC, sjogren syndrome, ulcerative colitis, and so on. \-

Locations (1)

The First Affiliated Hospital, School of Medicine, Zhejiang University

Hanzhou, Zhejiang, China

Outcomes

Primary Outcomes

single cell analysis of the colonic tissue of patients with severe crohn's disease

single cell analysis of the colonic tissue of patients with severe crohn's disease: inflammed and non-inflammed area from right colon or the terminal ileum

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.